Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27822678 | 0.85 | TRPA1 (0.53) | TRPA1FDPSCYP1A2CYP2C9CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL7744739 | 0.85 | TRPA1 (0.53) | TRPA1FDPSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25043590 | 0.83 | TRPA1 (0.55) | TRPA1FDPSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4445459 | 0.80 | TRPA1 (0.52) | TRPA1FDPSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10562388 | 0.79 | TRPA1 (0.56) | TRPA1FDPSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18096764 | 0.76 | TRPA1 (0.53) | TRPA1FDPSCYP1A2CYP2C9CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL28248128 | 0.76 | TRPA1 (0.62) | TRPA1CYP1A2CYP2C9CYP2C19TAAR1 | |
| SCHEMBL14713913 | 0.75 | TRPA1 (0.47) | TRPA1FDPSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL28352524 | 0.75 | TRPA1 (0.52) | TRPA1FDPSCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9577914 | 0.75 | CYP1A2 (0.55) | TRPA1FDPSCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406602-A2 | USE OF SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACIDS AND DERIVATIVES THEREOF AS AGGRECANASE INHIBITORS | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1406626-A2 | SULPHONYL ARYL HYDROXAMATES AND THEIR USE AS MMP INHIBITORS | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6716844-B2 | ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS | PHARMACIA CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-6696449-B2 | CONTROL DEGRADATION OF CONENCTING TISSUE; CARDIOVASCULAR DISORDERS | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-6683078-B2 | REDUCING DEGRADATION OF CONNECTIVE TISSUE DUE TO CANCER OR INFLAMMATION | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| EP-0984959-B1 | AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORP (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030171404-A1 | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors | PHARMACIA CORPORATION | 2003-09-11 | — | — | US | disclosed |
| US-20030073845-A1 | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors | PHARMACIA CORPORATION | 2003-04-17 | — | — | US | disclosed |
| WO-2003007930-A2 | USE OF SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACIDS AND DERIVATIVES THEREOF AS AGGRECANASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| US-20020173508-A1 | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds | PHARMACIA CORPORATION | 2002-11-21 | — | — | US | disclosed |
| US-6476027-B1 | N-hydroxy 4-sulfonyl butanamide compounds | MONSANTO COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-6362183-B1 | PROTEASE INHIBITORS; RHEUMATIC DISEASES; ANTITUMOR AGENTS | G. D. SEARLE & COMPANY | 2002-03-26 | — | — | US | disclosed |
| EP-0984959-A4 | AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS | MONSANTO CO (US) | 2001-05-02 | — | — | EP | disclosed |
| EP-0983258-A4 | N-HYDROXY 4-SULFONYL BUTANAMIDE COMPOUNDS | MONSANTO CO (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-0984959-A1 | AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0983258-A1 | N-HYDROXY 4-SULFONYL BUTANAMIDE COMPOUNDS | MONSANTO COMPANY (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998039326-A1 | AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998039316-A1 | N-HYDROXY 4-SULFONYL BUTANAMIDE COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073845-A1 | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors | ARSA, MMP1, MMP3 | TRPA1 1110/4885FDPS 2616/4885CYP1A2 920/4885 |
| US-20020173508-A1 | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds | MMP1, MMP2, MMP3 | TRPA1 3250/4885FDPS 2709/4885CYP1A2 2483/4885 |
| US-20030171404-A1 | Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors | ARSA, AADAC, ASPH | TRPA1 2775/4885FDPS 1663/4885CYP1A2 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.